Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Early real-world treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with eribulin after prior immuno-oncology or antibody–drug conjugate therapy. Clin Breast Cancer. 2023 Nov 16;15:855-65. doi: 10.2147/BCTT.S422025
Lennon RP, Sakya SM, Miller EL, Snyder B, Yaman T, Zgierska AE, Ruffin 4th MT, Van Scoy LJ. Public intent to comply with COVID-19 public health recommendations. Health Lit Res Pract. 2020 Aug 6;4(3):e161-5. doi: 10.3928/24748307-20200708-01
Block, Jr. R, Berg A, Lennon RP, Miller EL, Nunez-Smith M. African American adherence to COVID-19 public health recommendations. Health Lit Res Pract. 2020 Aug 6;4(3):e166-70. doi: 10.3928/24748307-20200707-01
Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, Stearn V. Treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR-/HER2– advanced breast cancer enrolled in an expanded access program. Clin Breast Cancer. 2019 Oct;19(5):317-25. doi: 10.1016/j.clbc.2019.04.005
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.